These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32732671)

  • 1. The Cancer Journal Article for Theme Issue: The Problem of Cancer Drug Costs.
    Collyar DE
    Cancer J; 2020; 26(4):292-297. PubMed ID: 32732671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Problem of Cancer Drugs Costs: A Payer Perspective.
    Newcomer LN
    Cancer J; 2020; 26(4):287-291. PubMed ID: 32732670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer Drugs in Asian Populations: Availability, Accessibility, and Affordability.
    Goh BC; Lim JF
    Cancer J; 2020; 26(4):323-329. PubMed ID: 32732675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In the Era of Cost-Effectiveness Analysis, Affordability Is a Limiting Factor for Patients' Access to Innovative Cancer Treatments.
    Aguiar PN; Adashek JJ; Roitberg F; Noia Barreto CM; Del Giglio A; Lopes GL
    Value Health Reg Issues; 2019 Dec; 20():47-50. PubMed ID: 30856543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obstacles to affordable cancer treatments.
    Dusetzina SB; Muluneh B; Khan T; Richards KL; Keating NL
    N C Med J; 2014; 75(4):257-60. PubMed ID: 25046090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pricing and Paying for Cancer Drugs: Policy Options for Fixing A Broken System.
    Hyman DA; Silver C
    Cancer J; 2020; 26(4):298-303. PubMed ID: 32732672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tackling Cost: A Prescription for Spending Wisely.
    Tempero M
    J Natl Compr Canc Netw; 2019 Jun; 17(6):633. PubMed ID: 31200360
    [No Abstract]   [Full Text] [Related]  

  • 9. Controlling the cost of innovative cancer therapeutics.
    Malik NN
    Nat Rev Clin Oncol; 2009 Sep; 6(9):550-2. PubMed ID: 19707244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 340b drug discount program: oncology's optical illusion.
    Eagle D; Buell RL; Vacirca J
    Oncology (Williston Park); 2013 Nov; 27(11):1068, 1070, 1072. PubMed ID: 24575533
    [No Abstract]   [Full Text] [Related]  

  • 11. THE MOST FAVORED NATIONS MODEL INTERIM FINAL RULE IS FATALLY FLAWED AND MUST BE RESCINDED-YET THE PROBLEM IT ADDRESSES DEMANDS A SOLUTION.
    Rubinstein E
    J Manag Care Spec Pharm; 2021 Feb; 27(2):286. PubMed ID: 33506733
    [No Abstract]   [Full Text] [Related]  

  • 12. Seeking value as cancer drug costs soar.
    Bender E
    Cancer Discov; 2013 Aug; 3(8):833-4. PubMed ID: 23928760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The just price of cancer drugs and the growing cost of cancer care: oncologists need to be part of the solution.
    Pfister DG
    J Clin Oncol; 2013 Oct; 31(28):3487-9. PubMed ID: 24002517
    [No Abstract]   [Full Text] [Related]  

  • 14. The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable.
    Prasad V; Mailankody S
    Mayo Clin Proc; 2016 Jun; 91(6):707-12. PubMed ID: 27261866
    [No Abstract]   [Full Text] [Related]  

  • 15. Perspectives on Cost and Value in Cancer Care.
    Saltz LB
    JAMA Oncol; 2016 Jan; 2(1):19-21. PubMed ID: 26501848
    [No Abstract]   [Full Text] [Related]  

  • 16. Empower physicians to fight financial toxicity with biosimilars.
    Oubre K
    Am J Manag Care; 2019 Dec; 25(12 Spec No.):SP374-SP375. PubMed ID: 31860250
    [No Abstract]   [Full Text] [Related]  

  • 17. Attitude of Iranian Medical Oncologists Toward Economic Aspects, and Policy-making in Relation to New Cancer Drugs.
    Daroudi R; Mirzania M; Zendehdel K
    Int J Health Policy Manag; 2015 Oct; 5(2):99-105. PubMed ID: 26927395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient Financial Assistance Programs: A Path to Affordability or a Barrier to Accessible Cancer Care?
    Zafar SY; Peppercorn JM
    J Clin Oncol; 2017 Jul; 35(19):2113-2116. PubMed ID: 28459612
    [No Abstract]   [Full Text] [Related]  

  • 19. Can we achieve affordable cancer medicine prices? Developing a pathway for change.
    Vogler S
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):321-325. PubMed ID: 33653228
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost effectiveness and cancer drugs.
    Battley JE; Connell LC; Graham DM; O'Reilly S
    J Clin Oncol; 2014 Apr; 32(10):1091-2. PubMed ID: 24590642
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.